SCHEMBL29446409

SCHEMBL29446409

CCCn1c(=S)[nH]c2c(oc3ccccc32)c1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 9/20 0.61
▸ ALDH1A1 P00352 6/20 0.61
▸ HTT P42858 3/20 0.61
▸ TSHR P16473 1/20 0.61
▸ HSD17B10 Q99714 1/20 0.61
▸ PPARG P37231 7/20 0.61
▸ NR2E3 Q9Y5X4 7/20 0.61
▸ NCOR2 Q9Y618 7/20 0.61
▸ NPSR1 Q6W5P4 4/20 0.59
▸ LMNA P02545 3/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ KDM4E B2RXH2 2/20 0.54
▸ ERCC5 P28715 1/20 0.51
▸ FEN1 P39748 1/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ MPO P05164 2/20 0.46
▸ MAPT P10636 1/20 0.45
▸ HAVCR2 Q8TDQ0 1/20 0.45
▸ PLK1 P53350 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29446454 0.81 RXFP1 (0.50) RXFP1ALDH1A1HTTTSHRHSD17B10
SCHEMBL26851462 0.74 PLK1 (0.68) PLK1APOBEC3G
SCHEMBL29446432 0.72 ALDH1A1 (0.73) RXFP1ALDH1A1KMT2AKDM4EERCC5
SCHEMBL7889976 0.69 ALDH1A1 (0.64) ALDH1A1HSD17B10LMNAKDM4ESMN1; SMN2
SCHEMBL12713432 0.69 MPO (0.73) ALDH1A1KMT2AKDM4ESMN1; SMN2MPO
SCHEMBL29446426 0.69 ALDH1A1 (0.52) ALDH1A1TSHRLMNAKMT2AKDM4E
SCHEMBL1892298 0.68 FEN1 (1.00) RXFP1ALDH1A1HTTTSHRHSD17B10
SCHEMBL18774623 0.66 ERCC5 (0.56) RXFP1ALDH1A1HTTTSHRHSD17B10
SCHEMBL26851524 0.66 PLK1 (0.67) ALDH1A1SMN1; SMN2MAPTPLK1APOBEC3G
SCHEMBL29446429 0.66 ALDH1A1 (0.64) RXFP1ALDH1A1HTTPPARGNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216958-A2 PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2023-08-02 — — EP disclosed
WO-2022067100-A2 PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2022-03-31 — — WO disclosed
Send feedback